#USA #New York #Pomerantz LLP #Dyne Therapeutics #DYN

Pomerantz Law Firm Investigates Dyne Therapeutics

Pomerantz LLP, a leading law firm known for its focus on corporate and securities litigation, is currently investigating potential claims for investors of Dyne Therapeutics, Inc. (NASDAQ: DYN). Recent developments surrounding the company raise significant concerns about possible securities fraud and unlawful business practices that investors should be aware of.

Background on Dyne Therapeutics

Dyne Therapeutics specializes in developing innovative therapies for genetic diseases, with its most notable candidate being DYNE-101, aimed at treating myotonic dystrophy type 1 (DM1). On June 17, 2025, Dyne issued a crucial press release indicating a delay in filing for U.S. Food and Drug Administration (FDA) approval for DYNE-101, a disclosure that has drawn the scrutiny of both investors and legal experts alike.

Delay in FDA Approval

The announcement came after a Type C meeting with the FDA where Dyne agreed to modify the protocol for its ongoing Phase 1/2 global ACHIEVE trial for DYNE-101. Previously, Dyne had laid out a timeline aiming to complete enrollments in the trial’s Registrational Expansion Cohort by mid-2025, with regulatory submissions expected in the first half of 2026. The revised schedule now pushes the enrollment completion date to the fourth quarter of 2025, with data expected by mid-2026 and possible Accelerated Approval submission planned for late 2026.

This significant shift in timeline raises questions about Dyne’s internal operations and the communication with investors. Following this news, the stock experienced a dramatic decline, plummeting $2.96 or 21.42%, closing at $10.86 per share on the day of the announcement. Such a steep drop has prompted Pomerantz LLP to take action on behalf of the affected investors.

Legal Implications

Investors who suffered a loss due to the stock price decrease are encouraged to connect with Pomerantz LLP. The firm is advising affected shareholders to reach out to Danielle Peyton at 646-581-9980, as potential securities fraud claims are being explored. Whether the company and its senior officers were complicit in misleading the market about the timeline for FDA approval could have serious implications for the future stability of the company's stock and its overall market reputation.

Pomerantz LLP’s Role

With a storied history exceeding 85 years, Pomerantz LLP has been at the forefront of securities law and class action litigation. The firm was the pioneer in class action lawsuits, championing the rights of investors who have fallen victim to corporate malfeasance. Historically, Pomerantz has successfully recovered numerous multimillion-dollar settlements for its clients.

The firm's extensive experience in securities litigation positions it uniquely to navigate the complexities surrounding this case. If you believe you have been affected by Dyne’s recent actions, now is the time to take action and seek expert legal guidance.

Conclusion

The investigation by Pomerantz LLP highlights the ongoing vulnerabilities that investors face in the biotech sector, where delays in critical regulatory approvals can lead to significant financial repercussions. As Dyne Therapeutics navigates this period of uncertainty, affected investors must remain vigilant and consider their options moving forward, including potential legal avenues to recover losses.

If you are an investor in Dyne Therapeutics, don’t hesitate to reach out to the experienced team at Pomerantz LLP to understand your rights and available actions effectively.